SCHEMBL1011422

SCHEMBL1011422

Cc1cccc(Oc2cccc(CO)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.46
KDR P35968 1/20 0.42
F2 P00734 2/20 0.42
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
GPBAR1 Q8TDU6 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.42
PPARG P37231 1/20 0.42
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
BRD4 O60885 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FFAR1 O14842 2/20 0.39
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM5 P41594 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010860 0.84 F2 (0.44) F10F2PPARGCYP1A2MAPT
SCHEMBL31538464 0.84 LTA4H (0.50) F10F2CYSLTR1PPARGFFAR1
SCHEMBL18586073 0.84 F10 (0.44) F10KDRNR1H2NR1H3GPBAR1
SCHEMBL5114439 0.82 FFAR1 (0.56) KDRNR1H2NR1H3PPARGFFAR1
SCHEMBL18993113 0.82 F10 (0.44) F10KDRF2NR1H2NR1H3
SCHEMBL27209666 0.81 F10 (0.42) F10KDRF2NR1H2NR1H3
SCHEMBL19755771 0.79 GRM5 (0.53) F10KDRNR1H2NR1H3GPBAR1
SCHEMBL27233665 0.79 NR1H2 (0.46) F10KDRNR1H2NR1H3GPBAR1
SCHEMBL17720580 0.78 MAP4K4 (0.55) F10F2PPARGCYP1A2MAPT
SCHEMBL29279703 0.78 PPARG (0.40) F10F2PPARGL3MBTL1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC F10 1445/4885KDR 4386/4885F2 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.